Abelacimab
MAA868Antibody Factor XIa inhibitor with potential for safer anticoagulation than DOACs. AZALEA-TIMI-71 in AF was halted Sep 2023 for overwhelming benefit (positive). VTE program (ASTER, MAGNOLIA) terminated.
Emerging drug — Phase 3 readout — MIXED
~ Mixed · Read out 2025-01-22AZALEA-TIMI 71 (n=1,287) showed unprecedented 67% bleeding reduction vs rivaroxaban (3.5% vs 10.6%) in atrial fibrillation patients — published NEJM Jan 2025; trial stopped early Sept 2023 by IDMC for overwhelming benefit. HOWEVER, the pivotal stroke-prevention Phase 3 (LILAC-TIMI 76) is still ongoing with completion anticipated H2 2026. The bleeding endpoint is resolved; the stroke-efficacy endpoint is not.
Regulatory: Bleeding-superiority shown vs DOAC; stroke-prevention efficacy pending LILAC readout.
→ Source PRNext remaining catalyst
Fresh est.A positive readout makes F11 a validated target for the first time. Hover the badge above for what the confidence level means.
What does it do?
F11 — Coagulation Factor XI / FXIa
Modality: monoclonal antibody (anti-FXI/FXIa)
Program: AZALEA-TIMI-71, ASTER, MAGNOLIA
The 3 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT05171049 | Venous Thromboembolism; Deep Venous Thrombosis | 1,150 | TERMINATED | 2022-05-05 | 2026-02-04 | Stale est. |
| NCT05171075 | Venous Thromboembolism; Deep Venous Thrombosis | 417 | TERMINATED | 2022-09-27 | 2026-04-10 | Stale est. |
| NCT05712200 | Atrial Fibrillation (AF) | 1,900 | RECRUITING | 2022-12-27 | 2026-08-31 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2019 | spinout | Novartis (origin spinout) | $250M (Anthos formation) |
What's the case for and against?
✓ What's working in its favor
- AZALEA-TIMI-71 stopped early Sep 2023 for >60% reduction in major bleeding vs rivaroxaban — positive readout
⚠ What's the biggest risk
- ASTER trial (cancer-associated VTE): terminated
- MAGNOLIA trial (cancer-associated VTE): terminated
Who else is racing? — 5 other assets at F11
| Asset | Sponsor | Status |
|---|---|---|
| REGN9933 | Regeneron | P3 active in AF and PAD |
| Asundexian (BAY2433334) | Bayer | P3 OCEANIC-AF halted 2023 (futility) |
| Milvexian (BMS-986177) | BMS/Janssen | P3 in stroke (LIBREXIA) |
| Fesomersen (BAY2976217) | Bayer/Ionis | P2 ASO |
| KN060 | Suzhou Alphamab | P2 |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.